Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease

M Ratcliffe, C Broadfoot, M Davidson, K F Kelly, M Greaves

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Markers of thrombotic risk - fibrinogen, factor VIII and immunoglobulin G (IgG) anticardiolipin titres - were measured, and the presence of lupus anticoagulant and factor V Leiden were assessed in 84 patients with a solid or haematological malignancy. These patients were monitored, following the insertion of an indwelling venous catheter, for thrombosis. Fifty-five were given prophylactic low-dose warfarin. Over a mean of 15 weeks there were 10 (12%) thrombotic events in 10 patients. Seven were on warfarin. Haemorrhagic problems occurred in three (5%), all on warfarin. Of the 84 patients, 86% had raised fibrinogen levels, 37% elevated factor VIII and 44% raised anticardiolipin levels. Lupus anticoagulant was present in five and three were heterozygous for factor V Leiden. A high prevalence of a range of prothrombotic changes was confirmed and the frequent presence of low-titre anticardiolipin antibody in subjects with malignancy demonstrated. However, none of these parameters predicted the development of thrombosis (P > 0.05).

Original languageEnglish
Pages (from-to)353-357
Number of pages5
JournalClinical and Laboratory Haematology
Volume21
Publication statusPublished - 1999

Keywords

  • catheters
  • malignancy markers
  • prophylaxis
  • thrombosis
  • LOW-MOLECULAR-WEIGHT
  • CANCER-PATIENTS
  • LUPUS ANTICOAGULANT
  • ACCESS DEVICES
  • HEPARIN
  • COMPLICATIONS

Cite this

Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease. / Ratcliffe, M ; Broadfoot, C ; Davidson, M ; Kelly, K F ; Greaves, M .

In: Clinical and Laboratory Haematology, Vol. 21, 1999, p. 353-357.

Research output: Contribution to journalArticle

@article{ae402e592efd48eeb17c0236acc7afa8,
title = "Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease",
abstract = "Markers of thrombotic risk - fibrinogen, factor VIII and immunoglobulin G (IgG) anticardiolipin titres - were measured, and the presence of lupus anticoagulant and factor V Leiden were assessed in 84 patients with a solid or haematological malignancy. These patients were monitored, following the insertion of an indwelling venous catheter, for thrombosis. Fifty-five were given prophylactic low-dose warfarin. Over a mean of 15 weeks there were 10 (12{\%}) thrombotic events in 10 patients. Seven were on warfarin. Haemorrhagic problems occurred in three (5{\%}), all on warfarin. Of the 84 patients, 86{\%} had raised fibrinogen levels, 37{\%} elevated factor VIII and 44{\%} raised anticardiolipin levels. Lupus anticoagulant was present in five and three were heterozygous for factor V Leiden. A high prevalence of a range of prothrombotic changes was confirmed and the frequent presence of low-titre anticardiolipin antibody in subjects with malignancy demonstrated. However, none of these parameters predicted the development of thrombosis (P > 0.05).",
keywords = "catheters, malignancy markers, prophylaxis, thrombosis, LOW-MOLECULAR-WEIGHT, CANCER-PATIENTS, LUPUS ANTICOAGULANT, ACCESS DEVICES, HEPARIN, COMPLICATIONS",
author = "M Ratcliffe and C Broadfoot and M Davidson and Kelly, {K F} and M Greaves",
year = "1999",
language = "English",
volume = "21",
pages = "353--357",
journal = "Clinical and Laboratory Haematology",
issn = "0141-9854",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease

AU - Ratcliffe, M

AU - Broadfoot, C

AU - Davidson, M

AU - Kelly, K F

AU - Greaves, M

PY - 1999

Y1 - 1999

N2 - Markers of thrombotic risk - fibrinogen, factor VIII and immunoglobulin G (IgG) anticardiolipin titres - were measured, and the presence of lupus anticoagulant and factor V Leiden were assessed in 84 patients with a solid or haematological malignancy. These patients were monitored, following the insertion of an indwelling venous catheter, for thrombosis. Fifty-five were given prophylactic low-dose warfarin. Over a mean of 15 weeks there were 10 (12%) thrombotic events in 10 patients. Seven were on warfarin. Haemorrhagic problems occurred in three (5%), all on warfarin. Of the 84 patients, 86% had raised fibrinogen levels, 37% elevated factor VIII and 44% raised anticardiolipin levels. Lupus anticoagulant was present in five and three were heterozygous for factor V Leiden. A high prevalence of a range of prothrombotic changes was confirmed and the frequent presence of low-titre anticardiolipin antibody in subjects with malignancy demonstrated. However, none of these parameters predicted the development of thrombosis (P > 0.05).

AB - Markers of thrombotic risk - fibrinogen, factor VIII and immunoglobulin G (IgG) anticardiolipin titres - were measured, and the presence of lupus anticoagulant and factor V Leiden were assessed in 84 patients with a solid or haematological malignancy. These patients were monitored, following the insertion of an indwelling venous catheter, for thrombosis. Fifty-five were given prophylactic low-dose warfarin. Over a mean of 15 weeks there were 10 (12%) thrombotic events in 10 patients. Seven were on warfarin. Haemorrhagic problems occurred in three (5%), all on warfarin. Of the 84 patients, 86% had raised fibrinogen levels, 37% elevated factor VIII and 44% raised anticardiolipin levels. Lupus anticoagulant was present in five and three were heterozygous for factor V Leiden. A high prevalence of a range of prothrombotic changes was confirmed and the frequent presence of low-titre anticardiolipin antibody in subjects with malignancy demonstrated. However, none of these parameters predicted the development of thrombosis (P > 0.05).

KW - catheters

KW - malignancy markers

KW - prophylaxis

KW - thrombosis

KW - LOW-MOLECULAR-WEIGHT

KW - CANCER-PATIENTS

KW - LUPUS ANTICOAGULANT

KW - ACCESS DEVICES

KW - HEPARIN

KW - COMPLICATIONS

M3 - Article

VL - 21

SP - 353

EP - 357

JO - Clinical and Laboratory Haematology

JF - Clinical and Laboratory Haematology

SN - 0141-9854

ER -